Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell   sector : Process industries    save search
ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
IBRX | $4.94 -6.26% 10.83% 4.5M twitter stocktwits trandingview |
Manufacturing
 | | O: 1.53% H: 1.2% C: -2.41%
AMRS | $0.05 -21.88% -16.36% 47M twitter stocktwits trandingview |
Process Industries
 | | O: -2.79% H: 1.93% C: -3.72%
als bladder cancer trials trial covid cel clinical trials cancer vaccine phase 3 merge t-cell bladder
Gainers vs Losers
73% 27%

Top 10 Gainers
AGBA | $2.5 100.0% 58.33% 200M twitter stocktwits trandingview |
Finance
EDBL | News | $6.26 66.49% 48.56% 270K twitter stocktwits trandingview |

MLEC | $2.47 76.43% 38.05% 460K twitter stocktwits trandingview |
n/a
SILO | $1.99 0.71% 20.64% 1.8M twitter stocktwits trandingview |
Finance and Insurance
NNVC | $1.12 1.82% 19.64% 2.5K twitter stocktwits trandingview |
Health Technology
CANG | $1.34 -4.29% 14.93% 120K twitter stocktwits trandingview |
Technology Services
AZTR 4 | $0.195 13.85% 42K twitter stocktwits trandingview |
n/a
TOVX | News | $0.411 -1.01% 12.9% 230K twitter stocktwits trandingview |
Manufacturing
IBRX | $4.94 -6.26% 10.83% 4.5M twitter stocktwits trandingview |
Manufacturing
MSTR M | $1324.01 12.77% 10.65% 26K twitter stocktwits trandingview |
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.